LifeStance (NASDAQ: LFST) director reports 9,376-share tax withholding on RSU vesting
LifeStance Health Group director Ryan Pardo reported a tax-related withholding of 9,376 shares of common stock at $6.37 per share to cover tax obligations from restricted stock units that vested on March 9, 2026. This was a routine transaction, not an open-market sale. After the withholding, Pardo directly held 1,093,366 shares, with an additional 2,551,520 shares held indirectly by a trust.
Tudor Investment Corp ET AL Takes Position in LifeStance Health Group, Inc. $LFST
Tudor Investment Corp has initiated a new position in LifeStance Health Group (NASDAQ: LFST) by acquiring 189,038 shares valued at approximately $1.04 million. This comes as institutional ownership in the company stands at 85.50%, despite director Darren M. Black selling over 4 million shares. Several brokerages have upgraded LFST to "Buy" ratings, with a consensus "Moderate Buy" and an average target price of $9.83.
Frontline Honors Award Winner: Jacquelyn Girdlestone, Clinical Director, LifeStance Health
Jacquelyn Girdlestone, Clinical Director at LifeStance Health, has been recognized with a Frontline Honors Award for her dedicated work in the behavioral health industry. In an interview, she discusses her journey into the field, the misconceptions she's overcome, and her optimism for its future, emphasizing the importance of trust and sustainability for frontline workers. Her insights highlight the crucial role of supporting clinicians to ensure effective and compassionate care.
LifeStance Health Group, Inc. - Common Stock (NQ: LFST)
This article provides news headlines related to LifeStance Health Group, Inc. (LFST), focusing on investigations announced by various law firms on behalf of investors in August 2021. The listed headlines indicate potential securities fraud investigations. The page also displays current stock information and links to various financial data sections.
LifeStance Health (LFST) officer has 24,255 shares withheld for RSU taxes
LifeStance Health Group, Inc. officer Ryan McGroarty had 24,255 shares of common stock withheld at $6.45 per share to cover tax obligations from vested restricted stock units (RSUs) on March 24, 2026. This transaction was not an open-market sale, and after the withholding, McGroarty directly holds 772,235 shares. The filing indicates a routine tax-related disposition connected to RSU vesting.
LifeStance (NASDAQ: LFST) officer RSU vesting leads to tax withholding
LifeStance Health Group, Inc. reported that officer Ryan McGroarty had restricted stock units vest on March 17, 2026. To cover tax obligations, 47,594 shares of common stock were withheld at $6.89 per share. This was a tax-withholding disposition, not an open-market sale, and McGroarty now directly holds 796,490 shares of LifeStance common stock.
BTIG maintains LifeStance Health Group (LFST) buy recommendation
BTIG has reiterated its Buy recommendation for LifeStance Health Group (LFST). This indicates the firm's continued positive outlook on the company's stock performance.
LifeStance Health Group, Inc. (NASDAQ:LFST) Receives Consensus Recommendation of "Moderate Buy" from Analysts
LifeStance Health Group (NASDAQ:LFST) has received a "Moderate Buy" consensus rating from analysts, with six firms recommending a buy, two a hold, and one a strong buy, and an average 12-month target price of $9.83. The company missed EPS estimates but beat revenue expectations, and its board approved a $100 million share buyback program. Despite analyst upgrades and institutional investor interest, significant insider selling has occurred.
LifeStance Health Appoints Lisa Miller as Chief Operating Officer
LifeStance Health Group has appointed Lisa Miller, 52, as its new Chief Operating Officer and Principal Operating Officer, effective March 10, 2026. Miller's compensation package, including a $485,000 base salary and performance-based equity awards, is structured to align her incentives with the company's growth goals. Analysts currently rate LFST stock as a Buy with a $9.00 price target, though Spark, TipRanks’ AI Analyst, gives it a Neutral rating due to valuation risks despite improving fundamentals.
Short Interest in LifeStance Health Group, Inc. (NASDAQ:LFST) Expands By 32.8%
Short interest in LifeStance Health Group (NASDAQ:LFST) significantly increased by 32.8% in February, totaling over 10.3 million shares. This comes as the company's board approved a $100 million share buyback, suggesting management believes the stock is undervalued, despite recent mixed earnings results. Analysts largely rate LFST as a "Moderate Buy" with a target price of $9.83, even though insiders have sold a substantial number of shares.
Integral Health Asset Management LLC Takes $8.25 Million Position in LifeStance Health Group, Inc. $LFST
Integral Health Asset Management LLC has acquired a significant stake of 1.5 million shares, valued at $8.25 million, in LifeStance Health Group, Inc. (NASDAQ:LFST), representing 0.39% ownership. This move comes as LifeStance, a leading provider of outpatient mental health services, authorized a $100 million share repurchase program and reported mixed Q3 results with revenue up 17.4% year-over-year. Analysts have a generally positive outlook, assigning a "Moderate Buy" consensus and an average price target of $9.83.
LifeStance Health Stock Analysis: Outperformance vs. Financial Risk - News and Statistics
LifeStance Health Group's stock has significantly outperformed the S&P 500, with its share price rising to $6.58. However, concerns remain regarding its relatively small industry presence with $1.42 billion in revenue, negative return on invested capital over five years, and a break-even free cash flow. Despite a reasonable forward price-to-earnings multiple of 22.7, the analysis advises avoiding the stock due to underlying business risks.
LifeStance Health Group (LFST) elevates Lisa Miller to Chief Operating Officer
LifeStance Health Group (LFST) has promoted Lisa Miller to Chief Operating Officer and Principal Operating Officer, effective March 10, 2026. In her new role, Miller will receive an annual base salary of $485,000, an annual target bonus of 85% of her base salary, and annual equity awards valued at approximately $1.5 million. These equity awards include both time-based and performance-based restricted stock units.
LifeStance (LFST) COO reports RSU and PSU vesting with 28,212 shares withheld for taxes
LifeStance Health Group, Inc. COO Lisa K. Miller reported equity compensation activity, including the vesting of restricted stock units (RSUs) and performance-based restricted stock units (PSUs). On March 9, 2026, she acquired 26,836 shares of common stock, and 28,212 shares were withheld by the issuer to satisfy tax obligations related to these vested awards. Following these transactions, Miller directly owned 329,201 shares of common stock.
LifeStance Health (LFST) exec’s PSUs vest with shares withheld for taxes
Ryan McGroarty, an executive at LifeStance Health Group, Inc. (LFST), had performance-based restricted stock units (PSUs) vest on March 9, 2026. He acquired a total of 193,046 shares from these PSUs, with 76,573 shares withheld by the issuer at $6.91 per share to cover tax withholding obligations. After these transactions, McGroarty directly holds 844,084 shares of LifeStance common stock, and the withholding did not involve any open-market sales.
LifeStance (LFST) director gets major stock awards and tax withholding
LifeStance Health Group director Kenneth A. Burdick received significant stock awards through vested restricted stock units (RSUs) and performance-based restricted stock units (PSUs) totaling 740,504 shares on March 9, 2026. To cover tax obligations, the issuer withheld 327,209 shares at $6.91 per share, which were not open-market sales. Following these transactions, Burdick directly holds 3,425,315 shares and indirectly 46,511 shares through Burdick Family LLC.
LifeStance Health Appoints Lisa Miller as Chief Operating Officer
LifeStance Health Group (LFST) has appointed Lisa Miller as its new Chief Operating Officer, effective March 10, 2026. Her compensation package, including a base salary of $485,000, performance bonuses, and equity awards, is designed to align her incentives with the company's long-term growth. Analysts currently rate LFST stock as a "Buy" with a $9.00 price target, while TipRanks' AI Analyst, Spark, rates it as "Neutral" due to valuation risks despite improving fundamentals.
LifeStance (NASDAQ: LFST) grants CMO 115,107 restricted stock units
LifeStance Health Group, Inc. reported that its Chief Medical Officer, Stephanie Carin Eken, was granted 115,107 restricted stock units (RSUs) on March 5, 2026, as equity-based compensation. These RSUs, valued at $0.00 per share, represent a contingent right to receive one share of LifeStance common stock each. Following this grant, Eken's directly held interest totals 115,107 contingent shares.
LifeStance Health Group, Inc. $LFST Shares Acquired by Vanguard Group Inc.
Vanguard Group Inc. significantly increased its stake in LifeStance Health Group (NASDAQ:LFST) by 19.5%, acquiring an additional 2.38 million shares. This move increases Vanguard's total holdings to 14.61 million shares, representing 3.76% of the company. The article also notes that institutional investors now own approximately 85.5% of LifeStance Health Group, highlights recent financial performance including a revenue increase but missed EPS estimates, and mentions a new $100 million share buyback program.
Large TPG vehicle trims LifeStance (LFST) stake with 20.7M-share sale
A TPG-affiliated fund has reduced its stake in LifeStance Health Group (LFST) by selling 20,685,061 common shares at $7.01 each on March 2, 2026. This open-market sale, detailed in an SEC Form 4 filing, leaves 140,026,557 shares indirectly owned by TPG VIII Lynnwood Holdings Aggregation, L.P. The transaction is described as a block sale reflecting portfolio management rather than company-specific fundamentals, with TPG disclaiming beneficial ownership beyond pecuniary interests.
AustralianSuper Pty Ltd Makes New $17.06 Million Investment in LifeStance Health Group, Inc. $LFST
AustralianSuper Pty Ltd has made a significant new investment of $17.06 million in LifeStance Health Group, Inc. by purchasing over 3.1 million shares in the third quarter. This move makes AustralianSuper Pty Ltd a 0.80% owner of LifeStance Health Group. The article also notes other institutional investors increasing their holdings and recent insider stock sales, while providing financial performance details and analyst ratings for LFST.
What LifeStance Health Group (LFST)'s Profit Return, Buyback Plan, and Stock Offerings Mean For Shareholders
LifeStance Health Group (LFST) recently reported strong Q4 2025 results, demonstrating a return to profitability with $11.7 million net income and issuing optimistic 2026 revenue guidance. The company also announced a $100 million share repurchase plan and filed for new stock offerings, signaling a reshaping of its capital strategy to balance growth with shareholder returns. These actions, coupled with positive future projections like $2.0 billion revenue by 2028, aim to reinforce its investment narrative despite ongoing industry challenges.
LifeStance Health Group (Nasdaq:LFST) - Stock Analysis
This Simply Wall St analysis provides an overview of LifeStance Health Group (LFST), detailing its financial health, growth prospects, and recent performance. The report highlights analyst consensus for stock price growth, alongside observed insider selling, and discusses market dynamics like rising mental health demand and digital transformation impacting the company. It also includes key financial metrics, price history, and recent corporate news.
Lifestance Health Announces Secondary Offering and Share Repurchase
LifeStance Health Group (LFST) recently completed a secondary offering of 25,000,000 shares, with all proceeds going to selling stockholders. Coinciding with this, the company repurchased 7,000,000 of the offered shares, effectively reducing its public float. Analysts have a "Buy" rating on LFST with an $8.50 price target, while TipRanks’ AI Analyst, Spark, rates it "Neutral" due to valuation concerns despite improving fundamentals.
LifeStance Health Group agrees to repurchase 7M shares, underwritten offering totals 25M shares
LifeStance Health Group (LFST) entered an underwriting agreement for an offering of 25,000,000 common shares. The company agreed to repurchase 7,000,000 of these shares from the underwriter. LifeStance received no proceeds as all shares were sold by existing stockholders, and the offering closed on March 2, 2026.
[8-K] LifeStance Health Group, Inc. Reports Material Event | LFST SEC Filing - Form 8-K
LifeStance Health Group, Inc. filed an 8-K report detailing an underwriting agreement for a public offering of 25,000,000 shares of common stock by selling stockholders. The company did not receive any proceeds from this offering but agreed to repurchase 7,000,000 shares from the underwriter. The offering closed on March 2, 2026.
Canaccord Lifts PT on LifeStance Health Group (LFST) to $10 From $9, Here's Why
Canaccord has increased its price target for LifeStance Health Group (LFST) to $10 from $9, maintaining a Buy rating. This decision follows LifeStance's strong fiscal Q4 2025 results and positive 2026 guidance, which project continued growth in revenue and adjusted EBITDA. The company also reported an 18% increase in Q4 visit volumes and a 9% rise in its clinician base.
Canaccord Lifts PT on LifeStance Health Group (LFST) to $10 From $9, Here's Why
Canaccord Genuity has increased its price target for LifeStance Health Group (LFST) to $10 from $9, maintaining a Buy rating. This adjustment follows LifeStance's strong fiscal Q4 2025 results, which showed significant revenue and visit volume growth, along with robust 2026 guidance. The firm highlighted continued strong growth projections and a favorable reimbursement and utilization environment as key factors.
Canaccord Lifts PT on LifeStance Health Group (LFST) to $10 From $9, Here’s Why
Canaccord has increased its price target for LifeStance Health Group (LFST) to $10 from $9, maintaining a Buy rating. This adjustment follows strong fiscal Q4 2025 results and optimistic 2026 guidance, with projected revenue and adjusted-EBITDA growth of 15% and 24% respectively. The company reported significant increases in revenue, clinician base, and visit volumes, while also providing outpatient mental health services both virtually and in-person.
LFST Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of LifeStance Health Group, Inc. (LFST), detailing its income statement, balance sheet, cash flow, and key financial ratios through fiscal year 2025. It highlights the company's financial health signals such as profitability (low), growth (solid revenue increase), strong leverage, adequate liquidity, and cash-backed earnings. The analysis includes Altman Z-Score and Piotroski F-Score for risk assessment, along with detailed annual and quarterly financial metrics.
LifeStance Health Group (LFST) Profit Turn Challenges Skeptical Earnings Narratives
LifeStance Health Group (LFST) has shown a significant profit turn in FY 2025, with Q4 revenue reaching US$382.2 million and a basic EPS of US$0.03, moving from a loss to a profit. This shift challenges skeptical earnings narratives and supports bullish views on potential earnings growth and margin expansion. However, the company faces risks from increased competition, clinician turnover, and higher operational costs, while its current share price is above its DCF fair value, indicating a need for strong future growth to justify the valuation.
LifeStance Health Group (LFST) Profit Turn Challenges Skeptical Earnings Narratives
LifeStance Health Group (LFST) has shown a significant shift to profitability in FY 2025, with Q4 revenue reaching US$382.2 million and basic EPS turning from a loss to a profit of US$0.03. This positive earnings turn challenges previous skeptical narratives, but concerns remain regarding potential competition from AI, digital health apps, and rising clinician costs. The share price of US$6.96 significantly exceeds the DCF fair value estimate of US$3.02, indicating that current valuation heavily relies on strong future growth.
Canaccord Genuity Group Forecasts Strong Price Appreciation for LifeStance Health Group (NASDAQ:LFST) Stock
Canaccord Genuity Group has increased its price target for LifeStance Health Group (NASDAQ:LFST) to $10, maintaining a "buy" rating and implying a potential upside of nearly 44%. Despite missing Q4 EPS estimates, the company reported strong revenue growth, authorized a $100 million share repurchase program, and received several analyst upgrades, though recent insider selling and a secondary offering have created near-term downward pressure. Institutional investors have been actively adjusting their holdings, with several major firms increasing their stakes in LFST.
6 Analysts Assess LifeStance Health Gr: What You Need To Know
Six analysts have recently shared their assessments of LifeStance Health Gr (NASDAQ: LFST), showing a mix of bullish and somewhat bullish ratings over the past three months. The average 12-month price target has increased by 8.7% to $10.00, with a high estimate of $12.00 and a low of $8.00. While the company exhibits positive revenue growth, its net margin, Return on Equity, and Return on Assets are below industry averages, suggesting potential challenges in profitability and asset utilization despite a prudent debt management strategy.
Key facts: LifeStance Health posts $24.1M profit; announces share offering
LifeStance Health reported a significant turnaround, posting a $24.1 million profit from operations and a net income of $9.7 million, reversing previous losses. The company also announced a secondary offering of 25 million shares by stockholders, along with an authorized buyback of 7 million shares. Analyst firms UBS and Keybanc maintained 'Buy' and 'Overweight' ratings, respectively, and increased their price targets for LifeStance Health (LFST).
LifeStance Health Group, Inc. SEC 10-K Report
LifeStance Health Group, Inc. released its 2025 10-K report, detailing significant financial and operational growth, including a 14% increase in total revenue to $1,424.3 million and a return to profitability with a net income of $9.7 million. The company expanded its clinician network to 8,040, served over a million patients, and optimized its real estate footprint while navigating challenges like reimbursement rates and regulatory changes. LifeStance plans continued expansion and integration of mental and physical healthcare.
LifeStance Health Group, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:LFST) 2026-02-26
LifeStance Health Group, Inc. (NASDAQ:LFST) published its 2025 Q4 earnings call presentation, reporting an EPS of $0.09, which beat estimates by $0.03. The company also announced revenue of $382.20M, an increase of 17.42% year-over-year, beating estimates by $3.69M. This presentation provides detailed insights into their financial performance for the quarter.
LifeStance (LFST) returns to profit in 2025 and OKs $100M share repurchase
LifeStance Health Group (LFST) announced a return to profitability in 2025 with full-year net income of $9.7 million and revenue up 14% to $1.424 billion. The company also authorized a $100 million share repurchase program and provided a strong 2026 outlook, projecting revenue between $1.615 billion and $1.655 billion. Additionally, Executive Chairman Kenneth Burdick will transition to a non-executive role in March 2026.
Existing LifeStance investors to sell 25M shares as company buys back 7M
LifeStance Health Group (Nasdaq: LFST) announced that certain selling stockholders plan to offer 25,000,000 shares of common stock, with the company not receiving any proceeds from this sale. Concurrently, LifeStance has authorized the repurchase of 7,000,000 shares from the underwriter, J.P. Morgan, at the same price as the offering, provided the offering completes. Historically, similar secondary offerings have led to significant stock price drops, though the current reaction has been milder.
LifeStance Health Group Q4 Earnings Call Highlights
LifeStance Health Group (NASDAQ:LFST) reported strong Q4 and full-year 2025 results, exceeding expectations with significant revenue growth, improved clinician productivity, and record profitability and cash flow. The company issued 2026 guidance forecasting continued growth and margin expansion, authorized a $100 million share repurchase program, and plans a multi-year EHR implementation to enhance operational efficiency.
Key facts: LifeStance Health reports 14% revenue growth; Burdick named Non-Executive Chairman
LifeStance Health (LFST) announced a 14% revenue growth in 2025, reaching $1.42 billion, and projects 2026 revenue to be between $1.615 billion and $1.655 billion. Additionally, Kenneth Burdick will transition to the role of Non-Executive Chairman, as stated in a recent SEC filing. The company also provided Q1 2026 revenue guidance of $390 million.
LifeStance Health Group Announces Launch of Secondary Public Offering
LifeStance Health Group, Inc. (Nasdaq: LFST) announced a secondary public offering where certain stockholders intend to sell 25,000,000 shares of common stock. The company itself will not sell any shares or receive proceeds but will concurrently purchase 7,000,000 shares from the underwriter. The offering is not contingent on the share repurchase and J.P. Morgan is acting as the underwriter.
LifeStance Health Group (NASDAQ:LFST) Posts Better-Than-Expected Sales In Q4 CY2025, Stock Jumps 12.7%
LifeStance Health Group (NASDAQ:LFST) exceeded Wall Street's expectations for Q4 CY2025, reporting revenue of $382.2 million, a 17.4% year-on-year increase, and GAAP profit of $0.03 per share. The company also provided optimistic guidance for Q1 CY2026 revenue and full-year 2026 EBITDA, leading to a 12.7% jump in its stock. This strong performance marks an "exceptional year" for LifeStance, demonstrating sustained execution and healthy demand for its mental health services.
LifeStance Reports Fourth Quarter and Full Year 2025 Results
LifeStance Health Group, Inc. (Nasdaq: LFST) announced strong financial results for the fourth quarter and full year ended December 31, 2025, with significant revenue growth in both periods. The company highlighted increased clinician numbers and visit volumes, alongside positive net income and Adjusted EBITDA. Looking ahead to 2026, LifeStance anticipates continued revenue growth and has approved a $100 million share repurchase program.
Lifestance Health earnings up next: Path to profit in focus
Lifestance Health Group Inc. is expected to report its fourth-quarter results, with analysts anticipating a minimal loss per share on revenue of $378.45 million, marking 16% year-over-year growth. Investors will focus on the company's trajectory towards sustained profitability, its management of payer relationships, and its evolving real estate strategy amidst changes in telehealth demand. The company's recent performance showed breakeven earnings and strong revenue in Q3, with continued expansion of its clinician base.
LifeStance Health (NASDAQ: LFST) outlines 2025 scale, payor mix and risks
LifeStance Health Group, Inc. (NASDAQ: LFST) filed its annual report (Form 10-K) detailing its 2025 operations, highlighting its significant scale as a large outpatient mental health platform with 8,040 clinicians across 33 states, serving over 1 million unique patients through 9 million visits. The company reported that 90% of its 2025 revenue came from commercial in-network payors, with UnitedHealthcare and Elevance Health representing 14% and 15% of total revenue, respectively. The report also outlines key risks such as dependence on reimbursement rates, clinician recruitment and retention challenges, regulatory complexities, and intense competition in the mental health market.
LifeStance Health Group (NASDAQ:LFST) Posts Better-Than-Expected Sales In Q4 CY2025, Stock Jumps 12.7%
LifeStance Health Group (NASDAQ:LFST) reported stronger-than-expected sales in Q4 CY2025, with revenue up 17.4% year-over-year to $382.2 million, surpassing analyst estimates. The behavioral health company also provided optimistic revenue guidance for Q1 CY2026 and full-year 2026 EBITDA, both exceeding market expectations. Following these positive results, LifeStance Health Group's stock jumped 12.7%.
LifeStance Health Group, Inc. (NASDAQ:LFST) Given Average Rating of "Moderate Buy" by Brokerages
LifeStance Health Group (NASDAQ:LFST) has received a "Moderate Buy" consensus rating from nine brokerages, with an average 1-year price target of $9.00. The stock is currently trading near its 50-day moving average and above its 200-day moving average. Insider selling of 270,086 shares worth $1.89 million has been noted, while institutional investors hold approximately 85.50% of the company's stock.
Grief Counselling Market Report 2026-2035: A $5.83 Billion
The grief counseling market is projected to grow from $3.67 billion in 2025 to $5.83 billion by 2030, driven by increased mental health awareness, digital platform adoption, and investment in mental health services. Key opportunities include the expansion of community programs and integration into healthcare systems. North America currently leads the market, with Asia-Pacific expected to be the fastest-growing region.
Emotional Counseling Service Market Report 2026-2035: A $21.21 Billion Industry by 2030 with Cleveland Clinic, Teladoc Health., LifeStance, GoodRx, Thriveworks, Headspace, Lyra Health, MDLive Leading
The emotional counseling service market is projected to grow significantly from $4.72 billion in 2025 to $21.21 billion by 2030, driven by increased mental health awareness, digital therapy adoption, and expanding employer-sponsored services. Key trends include tele-counseling, personalized therapy plans, and AI-based wellness coaches. Major companies like Cleveland Clinic and Teladoc Health are leading this growth, with the Asia-Pacific region currently dominating the market.
